Opendata, web and dolomites

OXIFLOW SIGNED

Next Generation Flow Diverter for the Treatment of Intracranial Aneurysms Delivering Improved Patient Outcomes and Healthcare Cost Savings

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 OXIFLOW project word cloud

Explore the words cloud of the OXIFLOW project. It provides you a very rough idea of what is the project "OXIFLOW" about.

revenues    cheaper    vessels    healing    business    origami    delivering    forces    inferior    sah    market    ia    fim    resolution    severe    clipping    invasive    options    utilises    endovascular    51    suffer    vessel    causes    tortuous    away    surgical    463m    natural    expensive    extension    risk    whom    restrict    radial    56m    fd    innovative    principles    approvals    unruptured    mesh    complete    freeze    material    avoidable    patient    oe    coning    safety    die    shape    diverters    uniform    minimally    overcoming    central    thereby    performance    ias    haemorrhage    blood    ethical    intracranial    subarachnoid    aneurysm    fds    rupture    poorer    made    live    generating    first    man    each    entirely    expectations    citizens    coiling    addressable    small    failed    reporting    73    oxiflow    excellent    divert    40    pilot    procedure    limitations    risky    nitinol    memory    apposition    weak    device    cumulative    inherent    guidewire    clinical    treatment    porosity    disabilities    regulatory    02m    ing    whilst    manufacture    optimum    lower    flow    transfer    poor    period   

Project "OXIFLOW" data sheet

The following table provides information about the project.

Coordinator
OXFORD ENDOVASCULAR LIMITED 

Organization address
address: 9400, GARSINGTON ROAD, OXFORD
city: OXFORD
postcode: OX4 2HN
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country United Kingdom [UK]
 Total cost 4˙232˙828 €
 EC max contribution 2˙962˙979 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-2
 Funding Scheme SME-2
 Starting year 2019
 Duration (year-month-day) from 2019-06-01   to  2021-11-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    OXFORD ENDOVASCULAR LIMITED UK (OXFORD) coordinator 2˙962˙979.00

Map

 Project objective

Each year ~51,000 EU citizens suffer a subarachnoid haemorrhage (SAH) resulting from the rupture of an intracranial aneurysm (IA), of whom 40% will die and 40% will suffer severe disabilities. However, SAH’s are entirely avoidable through treatment of ‘at risk’ unruptured IAs.

Existing treatment options include: surgical clipping, an invasive, risky and expensive procedure but delivering excellent long-term resolution; and endovascular coiling, a cheaper and lower risk minimally invasive procedure but delivering poorer long-term resolution. Flow diverters (FDs) are an emerging endovascular device that divert blood flow away from the aneurysm thereby enabling natural healing. Whilst offering the potential of excellent long-term resolution at low risk and cost, existing FDs have failed to live up to expectations, reporting performance inferior to coiling. Limitations of existing FD’s are inherent to their mesh design that causes weak and non-uniform radial forces resulting in poor vessel apposition, variable porosity and device coning. Existing delivery systems also restrict use due to extension of the central guidewire during delivery.

OxiFlow is a unique FD design based on origami principles and made from a shape memory Nitinol material. The innovative design enables optimum and uniform radial forces thereby overcoming the limitations of existing FDs. Furthermore, OxiFlow utilises a novel delivery system enabling complete user control of the central guidewire extension and thus use in small and tortuous vessels.

OXIFLOW will evaluate safety and performance of the OxiFlow device through a 10-patient First-in-Man (FIM) study. Project activities include: device design freeze, transfer to pilot scale manufacture, pre-clinical testing; regulatory and ethical approvals; and FIM study implementation.

The addressable EU & US market for OxiFlow is estimated at €463M. OE target €40.02M business growth over a 5-year period generating €73.56M cumulative revenues.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "OXIFLOW" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "OXIFLOW" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

DNA DS (2019)

DNA Data storage

Read More  

ERGOVIAkinematix (2018)

New wearable measurement devices for Industry 4.0 based on gaming motion-capture system

Read More  

LiCrete (2018)

LiCrete - Light transmitting composite material for building purposes

Read More